Liquidity & Technical

Liquidity & Technical

Free float is the binding constraint here, not the tape. ADV of roughly ₹30 crore on a ₹43,856 crore market cap (under 7 basis points a day) means a five-day window at 20% of ADV clears barely 7 bps of market cap — enough for a ₹15 billion (~₹1,517 crore) fund to size a 2% position, not the ₹50 billion fund that probably wants the story. Technically, the tape is constructive but stretched: a golden cross printed yesterday (2026-05-19), price sits 9.3% above the freshly-minted 200-day, and today's session saw 6× average volume on a slightly negative close — a distribution tell into a 22% YTD move.

Price snapshot

The stock listed on 2025-07-21 at ₹570 and has compounded at roughly 37% in ten months. One-year/three-year/five-year returns are not yet computable — treat any long-window technical signal accordingly.

Critical chart: price vs 50- and 200-day SMAs

The trajectory is a textbook post-IPO reset: a listing-day pop to ₹843, a peak at ₹864 in September 2025, a six-month grind down to ₹579 by late January 2026, then a roughly 35% recovery into May. The current setup is a confirmed uptrend with stretched short-term internals — extension above 20-day rather than mean reversion to it.

Relative strength

No benchmark time-series is populated in this run (INDA series empty; no sector ETF mapped to Indian healthcare). We cannot score relative strength against the broad Indian market on the chart. What we can say from absolute returns:

ANTHEM is up 22.3% YTD and 15.0% over the trailing six months. India's Nifty Pharma index has historically run mid-teens annualised; on rough numbers ANTHEM is tracking ahead of the pharma cohort and slightly behind Nifty 50 over the 10-month listed life. Without a clean series we won't put a score on it.

Momentum: RSI and MACD histogram

RSI hit 76.9 on 2026-05-15 — fully overbought — and has rolled to 56.9 in three sessions. The MACD line is still positive (+20.2) but the histogram has turned negative for three straight days. This is not a "sell the breakout" signal, but it is unambiguous: the easy-money phase of the bounce off the January low is over, and the near-term burden of proof is on the buyers.

Volume, spikes, and realized volatility

The pattern in the top spikes is telling: the highest-volume sessions are evenly split between accumulation days off recent lows (Dec-11, Feb-05, Mar-27, Apr-08) and distribution days into recent highs (Mar-09, today). Today's 6× session closed in the lower half of an intraday ₹765–₹820 range — that is the classic post-overbought distribution signature, not the breakout extension a buyer would prefer to see.

Realized vol sits at 30.1% — the median band of the 10-month sample (p20: 27.0%, p50: 30.0%, p80: 33.6%). Translation: option-implied premia for hedging would be ordinary, not stressed. The market is not yet pricing the upside breakout as a regime change.

Institutional liquidity panel

This stock is capacity-constrained for institutional sizing. The numbers below assume normal-participation execution (10–20% of ADV) and a five-day completion target.

ADV and turnover

The 6.9 bps daily turnover is what you'd expect from a name with 74.67% promoter holding, six-month-old IPO lockup math, and an effective ~25% free float. Twelve-month annualised turnover of ~31% is below mid-cap norms (which typically run 50–80%) — meaning what trades isn't a sponsorship pool that recycles quickly.

Fund-capacity table

Read the table this way: the largest fund that can take a 5% position over five days at 20% participation is roughly ₹607 crore AUM (~₹6 billion). A ₹2,000 crore fund wanting a 5% weight needs to chop the entry into ~16 trading days (a month), with execution cost meaningfully above the 2.9% median intraday range each session.

Liquidation runway

A 1% issuer-level position takes roughly three to seven months to exit without becoming the print. That is the actionable boundary: positions above this size carry materially elevated holding-period risk because exit timing is no longer your decision.

Execution friction

Median intraday range over the last 60 sessions is 2.90% — above the 2% threshold flagged in our template as elevated impact cost. For large orders this is the dominant friction (not bid-ask), and it argues for working orders via VWAP / participation algorithms rather than market clips.

Bottom line on liquidity: the largest single-name position a five-trading-day window will absorb at 20% ADV pace is 7 basis points of market cap (~₹30 crore, equivalent to a 5% weight in a ₹600 crore fund or a 2% weight in a ₹1,500 crore fund). At 10% ADV pace, halve those numbers.

Technical scorecard and stance

Net score: 0 (neutral, with constructive trend offsetting cautious sponsorship read).

Stance — neutral, with a constructive trend offset by cautious sponsorship

The tape is in a confirmed uptrend off the January low with a fresh golden cross, but a 6× volume distribution day on a negative close right under the 52-week high suggests this is not a chase point. Two levels frame the next move:

• ₹873 (52w / all-time high): a daily close above on volume above the 50-day average would confirm the IPO-era ceiling has cracked. Until then, the breakout is on probation.
• ₹717 (rising 50-day SMA, roughly coincident with the late-March consolidation): a close below resets the bounce and opens a path back to the ₹628 December lows. The golden cross unwinds quickly given how recent the SMA200 print is.

Liquidity is the constraint. For a fund under ~₹600 crore AUM this name is implementable at a 5% weight over a week; for anything materially larger the disciplined approach is watchlist with phased entry over multiple weeks, sized to keep daily participation at or below 10% of ADV. Avoid market-clip entries given the 2.9% median intraday range. If the fundamental story (numbers tab) confirms the secular CRDMO growth case, building into weakness toward the 50-day is the lower-impact execution path.